GO:0001996 positive regulation of heart rate by epinephrine-norepinephrine: Adrenergic Chronotropy, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001996 describes the biological process in which circulating epinephrine or norepinephrine increases the rate of heart contraction, a phenomenon known as positive chronotropy.
• The process is initiated by catecholamine binding to beta-adrenergic receptors on cardiac pacemaker cells, leading to increased firing rate of the sinoatrial node.
• Plasma epinephrine and norepinephrine concentrations correlate with heart rate changes in various physiological and pathological states, including exercise, stress, and hypertension.
• Experimental models for studying this process include measurements of plasma catecholamines and heart rate under conditions such as mechanical ventilation, surgery, and pharmacological interventions.
• Dysregulation of this process is implicated in cardiovascular disorders such as essential hypertension and acute pulmonary edema, where altered catecholamine levels affect cardiac function.
• Research tools include radioenzymatic assays, HPLC, and telemetry for quantifying catecholamines and heart rate in animal and human studies.
Description
The regulation of heart rate by circulating catecholamines is a fundamental physiological process that enables rapid adaptation to stress, exercise, and other demands. GO:0001996, positive regulation of heart rate by epinephrine-norepinephrine, captures the specific event where epinephrine or norepinephrine in the bloodstream activates, maintains, or increases the rate of heart contraction. This process is critical for maintaining cardiac output and is tightly linked to the autonomic nervous system. Understanding its mechanisms is essential for researchers studying cardiovascular physiology, pharmacology, and disease states such as hypertension and heart failure. Experimental evidence from human and animal studies demonstrates that plasma epinephrine and norepinephrine levels are directly associated with changes in heart rate under various conditions, including chronic guanfacine therapy, exercise, and surgical stress. These findings underscore the importance of catecholamines in modulating cardiac chronotropy and provide a basis for investigating the molecular and cellular pathways involved.
positive regulation of heart rate by epinephrine-norepinephrine At A Glance
| GO ID | GO:0001996 |
|---|---|
| GO term | positive regulation of heart rate by epinephrine-norepinephrine |
| Ontology | biological_process |
| Synonym | increased chronotropy by epinephrine-norepinephrine; positive regulation of heart contraction rate by adrenaline-noradrenaline; stimulation of heart contraction rate by epinephrine-norepinephrine |
| Major function | Increases the rate of heart contraction in response to circulating epinephrine or norepinephrine |
| Related process | Adrenergic signaling, cardiac conduction, stress response |
| Key molecules | Epinephrine, norepinephrine, beta-adrenergic receptors, sinoatrial node cells |
| Physiological context | Exercise, stress, hypertension, heart failure |
What Is GO:0001996?
GO:0001996 is defined as the process in which the presence of epinephrine or norepinephrine in the bloodstream activates, maintains, or increases the rate of heart contraction. This biological process encompasses the signaling events triggered by these catecholamines that ultimately lead to an increased firing rate of the sinoatrial node, the heart's natural pacemaker. It is synonymous with terms such as increased chronotropy by epinephrine-norepinephrine and positive regulation of cardiac contraction rate by adrenaline-noradrenaline.
Why Is positive regulation of heart rate by epinephrine-norepinephrine Important in Cell Biology?
GO:0001996 is important because it represents a core mechanism by which the body rapidly adjusts cardiac output to meet metabolic demands. Circulating catecholamines can increase heart rate within seconds, and this process is essential for survival during fight-or-flight responses. Dysregulation of this process contributes to cardiovascular diseases such as hypertension, arrhythmias, and heart failure, making it a target for therapeutic interventions.
• Critical for acute stress response and exercise performance.
• Involved in the pathophysiology of essential hypertension.
• Modulated during mechanical ventilation and positive end-expiratory pressure.
• Affected by surgical stress and anesthesia.
• Relevant to acute pulmonary edema and brain natriuretic peptide release.
• Target of pharmacological agents like guanfacine and amrinone.
• Used as a biomarker in procedural hypertension during ablation.
• Influenced by environmental factors such as operating room noise.
• Key readout in studies of neurohormonal stress response.
• Provides a model for studying adrenergic receptor signaling in vivo.
What Happens During positive regulation of heart rate by epinephrine-norepinephrine?
Catecholamine Release and Circulation
In simple terms: Epinephrine and norepinephrine are released into the blood from the adrenal glands and sympathetic nerves.
The process begins with the release of epinephrine and norepinephrine into the bloodstream from the adrenal medulla and sympathetic nerve terminals. Plasma concentrations of these catecholamines increase in response to stress, exercise, or pharmacological stimuli. For example, during chronic guanfacine therapy, plasma epinephrine and norepinephrine levels are altered in parallel with changes in blood pressure and heart rate. Similarly, exercise-induced stress increases plasma catecholamines in obese men.
Binding to Beta-Adrenergic Receptors
In simple terms: The catecholamines bind to beta-adrenergic receptors on heart pacemaker cells.
Once in the bloodstream, epinephrine and norepinephrine bind to beta-adrenergic receptors (primarily beta-1) on the surface of sinoatrial node cells and other cardiac conduction tissues. This binding activates intracellular signaling cascades, including the Gs-protein-adenylyl cyclase-cAMP-PKA pathway, which ultimately increases the slope of the pacemaker potential and firing rate.
Increased Sinoatrial Node Firing Rate
In simple terms: The pacemaker cells fire more frequently, increasing heart rate.
Activation of beta-adrenergic receptors leads to increased intracellular cAMP and activation of protein kinase A, which phosphorylates ion channels and calcium-handling proteins. This results in a faster depolarization rate of the sinoatrial node, thereby increasing heart rate. This mechanism is observed in various physiological and pathological states, such as during mechanical ventilation with positive end-expiratory pressure, where hormonal and tissue factors modulate heart rate.
Integration with Other Regulatory Pathways
In simple terms: Other hormones and neural signals can modify the heart rate response to catecholamines.
The positive chronotropic effect of epinephrine and norepinephrine is modulated by other factors, including angiotensin II, renin activity, and brain natriuretic peptide. For instance, during chronic guanfacine therapy, changes in plasma epinephrine and norepinephrine are related to blood pressure and heart rate, but angiotensin II and renin activity also play a role. In acute pulmonary edema, plasma brain natriuretic peptide concentrations are influenced by continuous positive airway pressure, which may indirectly affect heart rate.
Physiological and Clinical Manifestations
In simple terms: The increased heart rate helps the body respond to stress, but excessive activation can be harmful.
The end result of this process is an increased heart rate that enhances cardiac output during stress or exercise. Clinically, this process is relevant in conditions such as procedural hypertension during irreversible electroporation ablation of liver and pancreatic tumors, where distance from the adrenal gland affects catecholamine release and heart rate. Additionally, operating room noise can influence anxiety and pain, potentially affecting neurohormonal stress responses.
Key Genes Involved in GO:0001996 positive regulation of heart rate by epinephrine-norepinephrine
The following genes and proteins are key players in the positive regulation of heart rate by epinephrine-norepinephrine, based on their roles in catecholamine synthesis, signaling, and cardiac pacemaker function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor; mediates catecholamine signaling in heart | Target for heart rate modulation studies |
| ADRB2 | Beta-2 adrenergic receptor; also binds epinephrine/norepinephrine | Involved in vascular and cardiac responses |
| ADRA1A | Alpha-1A adrenergic receptor; modulates cardiac contractility | Potential cross-talk with beta-adrenergic signaling |
| TH | Tyrosine hydroxylase; rate-limiting enzyme in catecholamine synthesis | Determines norepinephrine and epinephrine production |
| DBH | Dopamine beta-hydroxylase; converts dopamine to norepinephrine | Key for norepinephrine synthesis |
| PNMT | Phenylethanolamine N-methyltransferase; converts norepinephrine to epinephrine | Regulates epinephrine levels |
| SLC6A2 | Norepinephrine transporter; reuptakes norepinephrine | Controls synaptic and plasma catecholamine levels |
| COMT | Catechol-O-methyltransferase; degrades catecholamines | Affects catecholamine clearance |
| MAOA | Monoamine oxidase A; degrades norepinephrine and epinephrine | Influences catecholamine half-life |
| HCN4 | Hyperpolarization-activated cyclic nucleotide-gated channel 4; pacemaker current | Directly regulates sinoatrial node firing rate |
| CACNA1C | L-type calcium channel; contributes to pacemaker potential | Modulated by beta-adrenergic signaling |
| SCN5A | Sodium channel; involved in cardiac action potential | Affects conduction velocity |
| RYR2 | Ryanodine receptor 2; calcium release in cardiomyocytes | Regulates calcium handling and heart rate |
| ATP2A2 | SERCA2; calcium reuptake in sarcoplasmic reticulum | Modulates cardiac relaxation and rate |
| GNAI2 | Gi protein alpha subunit; inhibits adenylyl cyclase | Counterbalances beta-adrenergic signaling |
| GNAS | Gs protein alpha subunit; activates adenylyl cyclase | Essential for beta-adrenergic signaling |
| PRKACA | Protein kinase A catalytic subunit; phosphorylates targets | Mediates downstream effects of cAMP |
| PDE4D | Phosphodiesterase 4D; degrades cAMP | Regulates cAMP levels in cardiac cells |
How Is positive regulation of heart rate by epinephrine-norepinephrine Regulated?
The process of positive regulation of heart rate by epinephrine-norepinephrine is regulated at multiple levels. Plasma catecholamine concentrations are controlled by release from adrenal medulla and sympathetic nerves, reuptake by transporters such as SLC6A2, and degradation by COMT and MAO. At the receptor level, beta-adrenergic receptor sensitivity and density are modulated by phosphorylation and desensitization mechanisms. Intracellular signaling is regulated by phosphodiesterases that degrade cAMP, and by phosphatases that reverse PKA-mediated phosphorylation. Additionally, other hormonal systems, such as the renin-angiotensin-aldosterone system, can modulate the heart rate response to catecholamines.
positive regulation of heart rate by epinephrine-norepinephrine and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRB1 | Hypertension, heart failure | Knockout mouse, point mutation |
| TH | Catecholamine dysregulation | Conditional knockout |
| SLC6A2 | Orthostatic intolerance | Knock-in of human variant |
| COMT | Pain sensitivity, hypertension | Overexpression |
| HCN4 | Sinus node dysfunction | Knock-in of pacemaker mutation |
Essential Hypertension
In patients with essential arterial hypertension, plasma epinephrine and norepinephrine concentrations are often elevated and correlate with blood pressure and heart rate. Chronic guanfacine therapy modulates these relationships, indicating that dysregulation of catecholamine-induced heart rate regulation contributes to hypertension pathophysiology.
Acute Pulmonary Edema
Acute pulmonary edema is associated with increased sympathetic activity and elevated plasma brain natriuretic peptide. Continuous positive airway pressure therapy affects these neurohormonal factors, which may influence heart rate regulation by catecholamines.
Procedural Hypertension
During irreversible electroporation ablation of liver and pancreatic tumors, procedural hypertension can occur due to catecholamine release from the adrenal gland. The distance from the adrenal gland affects the magnitude of hypertension and heart rate changes, highlighting the clinical relevance of GO:0001996.
Stress and Anxiety
Operating room noise can induce anxiety and pain, leading to neurohormonal stress responses that include catecholamine release and heart rate increases. This underscores the impact of environmental factors on this biological process.
From positive regulation of heart rate by epinephrine-norepinephrine-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ADRB1 mediate heart rate increase by epinephrine? | ADRB1 knockout mouse |
| What is the effect of a point mutation in HCN4 on heart rate? | HCN4 point-mutation knock-in mouse |
| Can overexpression of TH increase plasma norepinephrine? | Transgenic overexpression mouse |
| How does SLC6A2 variant affect catecholamine clearance? | SLC6A2 knock-in mouse |
| Is COMT involved in heart rate regulation? | COMT knockout mouse |
| What is the role of GNAS in beta-adrenergic signaling? | Conditional GNAS knockout |
How to Study the positive regulation of heart rate by epinephrine-norepinephrine Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC with electrochemical detection | Plasma epinephrine and norepinephrine concentrations | Clinical studies of stress and hypertension |
| Radioenzymatic assay | Catecholamine levels | Research on neurohormonal responses |
| ECG/Telemetry | Heart rate and rhythm | Animal and human monitoring |
| Beta-blocker challenge | Contribution of beta-adrenergic signaling | Pharmacological dissection |
| Knockout mouse models | Gene function in heart rate regulation | Target validation |
| CRISPR knock-in | Effect of specific mutations | Disease modeling |
| RNA-seq | Gene expression changes in heart tissue | Transcriptomic profiling |
Measurement of Plasma Catecholamines
Plasma epinephrine and norepinephrine concentrations are typically measured using high-performance liquid chromatography (HPLC) with electrochemical detection or radioenzymatic assays. These methods have been used to correlate catecholamine levels with heart rate in various clinical studies.
Heart Rate Monitoring
Heart rate can be monitored using electrocardiography (ECG) or telemetry in animal models and human subjects. In studies of procedural hypertension, heart rate is continuously recorded during ablation procedures.
Pharmacological Interventions
Drugs such as guanfacine, amrinone, and beta-blockers are used to modulate catecholamine release or receptor activity, allowing researchers to dissect the contribution of epinephrine and norepinephrine to heart rate regulation.
Genetic Models
Knockout, knock-in, and transgenic mouse models targeting adrenergic receptors, catecholamine synthesis enzymes, and ion channels are essential for understanding the molecular mechanisms of GO:0001996. These models allow precise manipulation of specific genes and assessment of their impact on heart rate responses.
How CRISPR Can Be Used to Study GO:0001996 positive regulation of heart rate by epinephrine-norepinephrine
Knockout
CRISPR knockout of genes such as ADRB1, TH, or SLC6A2 in cell models or mice can abolish or reduce the heart rate response to epinephrine and norepinephrine, helping to establish causality. For example, ADRB1 knockout mice show blunted heart rate increases to catecholamines.
Point Mutation
Introducing point mutations in genes like HCN4 or SCN5A can mimic human polymorphisms or disease-associated variants, allowing researchers to study their effects on heart rate regulation. CRISPR point mutation models are valuable for understanding subtle changes in channel function.
Knock-in
Knock-in of human variants, such as SLC6A2 polymorphisms, into mouse models can recapitulate human phenotypes related to catecholamine clearance and heart rate. This approach is useful for translational research.
Overexpression
Overexpression of genes like TH or PNMT using CRISPR activation or transgenic approaches can increase catecholamine production and elevate heart rate, providing a gain-of-function model to study GO:0001996.
How EDITGENE Supports positive regulation of heart rate by epinephrine-norepinephrine Research
Researchers studying positive regulation of heart rate by epinephrine-norepinephrine-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of heart rate by epinephrine-norepinephrine research.
Frequently Asked Questions About positive regulation of heart rate by epinephrine-norepinephrine
What is GO:0001996?
GO:0001996 is the Gene Ontology term for the biological process in which epinephrine or norepinephrine in the bloodstream increases the rate of heart contraction.
What genes are involved in positive regulation of heart rate by epinephrine-norepinephrine?
Key genes include ADRB1, ADRB2, TH, DBH, PNMT, SLC6A2, COMT, MAOA, HCN4, and CACNA1C, among others.
How does epinephrine increase heart rate?
Epinephrine binds to beta-adrenergic receptors on sinoatrial node cells, activating a signaling cascade that increases the firing rate of the pacemaker.
What is the role of norepinephrine in heart rate regulation?
Norepinephrine, released from sympathetic nerves, also binds to beta-adrenergic receptors and contributes to increased heart rate, especially during stress.
Which diseases are associated with dysregulation of this process?
Essential hypertension, acute pulmonary edema, and procedural hypertension are associated with altered catecholamine-induced heart rate regulation.
How can I study GO:0001996 in the lab?
You can measure plasma catecholamines by HPLC, monitor heart rate by ECG, and use CRISPR knockout or knock-in models to test gene function.
What CRISPR models are available for studying heart rate regulation?
EDITGENE offers knockout, point mutation, knock-in, and overexpression cell models for genes involved in this process.
What is the definition of positive chronotropy?
Positive chronotropy refers to an increase in heart rate, often mediated by epinephrine or norepinephrine.
How does guanfacine affect heart rate and catecholamines?
Chronic guanfacine therapy alters plasma epinephrine and norepinephrine levels, which correlate with changes in blood pressure and heart rate.
Can environmental factors influence this process?
Yes, factors such as operating room noise can induce stress and affect neurohormonal responses, including catecholamine release and heart rate.
Conclusion
GO:0001996, positive regulation of heart rate by epinephrine-norepinephrine, is a vital biological process that enables rapid cardiac adaptation to stress and metabolic demands. Its dysregulation is implicated in hypertension, pulmonary edema, and other cardiovascular conditions. Understanding the underlying molecular mechanisms through CRISPR-based models and pharmacological studies can reveal new therapeutic targets. EDITGENE provides essential tools to accelerate this research.
References
- 1. Wynands JE. 1989. Amrinone: is it the inotrope of choice?. J Cardiothorac Anesth 3(6 Suppl 2):45-57 PMID: 2521051
- 2. Li M et al.. 2025. Effects of Operating Room Noise on Anxiety and Pain in Non-General Anaesthesia Orthopaedic Surgery under Seamless Care and Diversified Health Education.. Noise Health 27(127):446-457 PMID: 40932080
- 3. Barbieri A et al.. 2004. Modifications of plasma concentrations of hormonal and tissue factors during mechanical ventilation with positive end-expiratory pressure.. Int Angiol 23(2):177-84 PMID: 15507897
- 4. Park J et al.. 2018. Exercise-induced changes in stress hormones and cell adhesion molecules in obese men.. J Inflamm Res 11:69-75 PMID: 29535548
- 5. Collart F et al.. 1985. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.. Acta Cardiol 40(3):269-76 PMID: 3895792
- 6. Migneault B et al.. 2004. The effect of music on the neurohormonal stress response to surgery under general anesthesia.. Anesth Analg 98(2):527-532 PMID: 14742400
- 7. Fang G et al.. 2020. Prevention of Procedural Hypertension in the Irreversible Electroporation Ablation of Liver and Pancreatic Tumors Based on Distance from the Adrenal Gland.. Cancer Manag Res 12:71-78 PMID: 32021424
- 8. Kelly CA et al.. 2002. Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations.. Eur Heart J 23(17):1379-86 PMID: 12191749
